Non-Hodgkin Lymphoma Clinical Trials

64 studies are recruiting for non-hodgkin lymphoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

   A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Emory Winship Cancer Institute, Atlanta, Georgia

   Locations

   39 in total

   Run by

   CellCentric Ltd.

   See if you can join NCT04068597 on ClinicalTrials.gov

2. Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

   This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   C. Babis Andreadis

   See if you can join NCT04545762 on ClinicalTrials.gov

3. Familial Investigations of Childhood Cancer Predisposition

   NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor …

   Stage

   Not phased

   Ages

   Any age

   Site

   St. Jude Children's Research Hospital, Memphis, Tennessee

   Run by

   St. Jude Children's Research Hospital

   See if you can join NCT03050268 on ClinicalTrials.gov

4. CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)

   The subject has a type of lymph gland cancer called Lymphoma. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. T cells, also called T lymphocyt…

   Stage

   Phase 1

   Ages

   12 to 75

   Site

   Houston Methodist Hospital, Houston, Texas

   Locations

   2 in total

   Run by

   Baylor College of Medicine

   See if you can join NCT02917083 on ClinicalTrials.gov

5. Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

   The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, n…

   Stage

   Not phased

   Ages

   0 to 38

   Site

   Children's Hospital Colorado, Aurora, Colorado

   Locations

   5 in total

   Run by

   Children's Hospital Medical Center, Cincinnati

   See if you can join NCT06131801 on ClinicalTrials.gov

6. Cord Blood Transplantation in Children and Young Adults With Blood Cancer

   The purpose of this study is to find out whether Cord Blood Transplantation/CBT as the first or second transplant is an effective treatment for children and young adults with blood cancer.

   Stage

   Phase 2

   Ages

   Up to 26

   Site

   Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07566377 on ClinicalTrials.gov

7. IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL

   This study is being done to determine the safety, efficacy and tolerability of a single 50 mCi dose of 131I-Apamistamab given prior to FDA approved (commercially available) infusion in patients with Relapsed or refractory (R/R) non-Hodgkin lymphoma.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas Southwestern Medical Center, Dallas, Texas

   Run by

   University of Texas Southwestern Medical Center

   See if you can join NCT06768905 on ClinicalTrials.gov

8. Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

   This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.

   Stage

   Phase 1

   Ages

   13 and older

   Site

   University of Chicago, Chicago, Illinois

   Locations

   8 in total

   Run by

   Newave Pharmaceutical Inc

   See if you can join NCT04771572 on ClinicalTrials.gov

9. Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

   To learn if the combination of pirtobrutinib (also called LOXO-305) and venetoclax can help to control mantle cell lymphoma (MCL) that is relapsed (has come back) or refractory (has not responded to therapy).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT05529069 on ClinicalTrials.gov

10. A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma

    A phase 2 multicenter study of VI-0609 vs BiCNU in the BEAM high-intensity conditioning regimen for AHCT in subjects with lymphomas.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    City of Hope Phoenix, Goodyear, Arizona

    Locations

    4 in total

    Run by

    VIVUS LLC

    See if you can join NCT06915246 on ClinicalTrials.gov

11. Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

    This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies with chemotherapy and/or (immune checkpoint inhibitors) ICIs.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Fairbanks Memorial Hospital, Fairbanks, Alaska

    Locations

    467 in total

    Run by

    Wake Forest University Health Sciences

    See if you can join NCT06418204 on ClinicalTrials.gov

12. CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

    This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs: * CD79b-19 CAR T cells * Fludarabine and Cyclopho…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Run by

    Marcela V. Maus, M.D.,Ph.D.

    See if you can join NCT06026319 on ClinicalTrials.gov

13. CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

    This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients undergoing hematopoietic stem cell transplant. Th…

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    City of Hope Medical Center, Duarte, California

    Locations

    3 in total

    Run by

    City of Hope Medical Center

    See if you can join NCT06059391 on ClinicalTrials.gov

14. SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas

    The goal of this clinical trial is to learn what dose of the drug SB-4826 can be given safely in patients with solid tumors and non-Hodgkin lymphomas. This drug will be used alone in patients with solid tumors, and will be used alone or in combination with rituximab in patients with non-Hodgkin lym…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, San Diego, La Jolla, California

    Run by

    University of California, San Diego

    See if you can join NCT07222631 on ClinicalTrials.gov

15. A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

    The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studie…

    Stage

    Phase 4

    Ages

    18 and older

    Site

    Sylvester Comprehensive Cancer Center, Miami, Florida

    Locations

    38 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT06876649 on ClinicalTrials.gov

16. A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

    Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned stu…

    Stage

    Phase 4

    Ages

    18 and older

    Site

    Sylvester Comprehensive Cancer Center, Miami, Florida

    Locations

    36 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT06876662 on ClinicalTrials.gov

17. Epco, Zanu, Ritux for R/R FL or MZL

    The purpose of this study is to determine how effective and safe the combination of epcoritamab, zanubrutinib, and rituximab is in treating participants with relapse or refractory Follicular Lymphoma (FL) or marginal zone lymphoma (MZL). * The names of the study drugs involved in this research stud…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Locations

    3 in total

    Run by

    Reid Merryman, MD

    See if you can join NCT06563596 on ClinicalTrials.gov

18. Study of SGR-1505 in Mature B-Cell Neoplasms

    The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Banner Health - MD Anderson Cancer Center, Gilbert, Arizona

    Locations

    36 in total

    Run by

    Schrödinger, Inc.

    See if you can join NCT05544019 on ClinicalTrials.gov

19. In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET

    The purpose of this study is to determine the uptake of the imaging agent [68Ga]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL), or you have histiocytic neoplasms (Langerhans ce…

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT05093335 on ClinicalTrials.gov

20. Improving Communication and Building a Stronger Medical Home Among Spanish-speaking Families

    This study will seek to improve communication with Spanish speaking families and patients with Cancer and Blood Disorders.

    Stage

    Not phased

    Ages

    Up to 22

    Site

    Children's Hospital Colorado, Aurora, Colorado

    Run by

    University of Colorado, Denver

    See if you can join NCT05425992 on ClinicalTrials.gov

21. Lifestyle Intervention of Food and Exercise for Lymphoma Survivors

    The purpose of this study is to investigate if a mediterranean diet and exercise program for Lymphoma patients during chemotherapy can improve treatment completion and reduce treatment-related side effects.

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Miami, Miami, Florida

    Run by

    University of Miami

    See if you can join NCT05839210 on ClinicalTrials.gov

22. Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

    The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified cellular therapy and have reported a qualifying second malignancy.

    Stage

    Not phased

    Ages

    Any age

    Site

    Ut Southwestern, Dallas, Texas

    Locations

    8 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT06357754 on ClinicalTrials.gov

23. Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

    Subjects on this study have a type of lymph gland cancer called Non-Hodgkin Lymphoma, acute lymphocytic leukemia, or chronic Lymphocytic Leukemia (these diseases will be referred to as "lymphoma" or "leukemia"). The lymphoma or leukemia has come back or has not gone away after treatment. The body h…

    Stage

    Phase 1

    Ages

    Up to 75

    Site

    Houston Methodist Hospital, Houston, Texas

    Locations

    2 in total

    Run by

    Baylor College of Medicine

    See if you can join NCT01853631 on ClinicalTrials.gov

24. PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy

    This is a phase I/Ib imaging study of granzyme B, 64-copper granzyme targeting restricted interaction peptide specific to family member B (64Cu-GRIP B) Positron Emission Tomography (PET) in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL) receiving CD19-directed Chimeric antigen recep…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    Michael Randall

    See if you can join NCT06522932 on ClinicalTrials.gov

25. Amping up With PemJAK

    The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractory Hodgkin and non-Hodgkin lymphomas.

    Stage

    Phase 2

    Ages

    18 to 95

    Site

    Columbia University Irving Medical Center, New York, New York

    Run by

    Seda S. Tolu

    See if you can join NCT07283822 on ClinicalTrials.gov